Page 101«..1020..100101102103..»

Skin cells turned into beating heart cells

By JoanneRUSSELL25

KIAH

12:01 p.m. CDT, May 30, 2012

How do you mend a broken heart? Thanks to scientists in Israel, we might soon have an answer.

Dr. Lior Gepstein and his team at Technion-Israel Institute of Technology managed to take skin cells from ailing heart patients and by adding three genes and valproic acid (used to treat epilepsy), they turned the cells into beating heart tissue.

And it was not just any old heart cells, but, according to Gepstein, "heart cells that are healthy, that are young and resemble heart cells at the day that the patient was born."

The researchers put the new beating heart tissue into rat hearts and saw it was not rejected, but seemed to establish connections with the rodents' tissue.

Stem cell experts praised the research as promising but urged people not to expect to be stopping by the clinic for a fresh heart any time soon. Gepstein's researchers say clinical trials should begin within the next 10 years.

See the rest here:
Skin cells turned into beating heart cells

To Read More: Skin cells turned into beating heart cells
categoriaSkin Stem Cells commentoComments Off on Skin cells turned into beating heart cells | dataMay 31st, 2012
Read All

Scientists turn skin cells into healthy heart tissue

By daniellenierenberg

Scientists turn skin cells into healthy heart tissue

Kate Kelland (Reuters) / 26 May 2012

The researchers said there were still many years of testing and refining ahead. But the results meant they might eventually be able to reprogramme patients cells to repair their own damaged hearts.

We have shown that its possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young - the equivalent to the stage of his heart cells when he was just born, said Lior Gepstein, who led the work.

The researchers, whose study was published in the European Heart Journal on Wednesday, said clinical trials of the technique could begin within 10 years.

Heart failure is a debilitating condition in which the heart is unable to pump enough blood around the body. It has become more prevalent in recent decades as advances in medical science mean many more people survive heart attacks. At the moment, people with severe heart failure have to rely on mechanical devices or hope for a transplant.

Researchers have been studying stem cells from various sources for more than a decade, hoping to capitalise on their ability to transform into a wide variety of other kinds of cell to treat a range of health conditions.

There are two main forms of stem cells - embryonic stem cells, which are harvested from embryos, and reprogrammed human induced pluripotent stem cells (hiPSCs), often originally from skin or blood.

Gepsteins team took skin cells from two men with heart failure aged 51 and 61 and transformed them by adding three genes and then a small molecule called valproic acid to the cell nucleus.

They found that the resulting hiPSCs were able to differentiate to become heart muscle cells, or cardiomyocytes, just as effectively as hiPSCs that had been developed from healthy, young volunteers who acted as controls for the study.

Originally posted here:
Scientists turn skin cells into healthy heart tissue

To Read More: Scientists turn skin cells into healthy heart tissue
categoriaSkin Stem Cells commentoComments Off on Scientists turn skin cells into healthy heart tissue | dataMay 27th, 2012
Read All

Skin Cells From Heart Failure Patients Made Into Healthy New Heart Muscle Cells

By Dr. Matthew Watson

Editor's Choice Main Category: Cardiovascular / Cardiology Article Date: 25 May 2012 - 0:00 PDT

Current ratings for: 'Skin Cells From Heart Failure Patients Made Into Healthy New Heart Muscle Cells'

4 (1 votes)

This achievement is significant, as it opens up the prospect of treating heart failure patients with their own, human-induced pluripotent stem cells (hiPSCs) to fix their damaged hearts.

Furthermore, the cells would avoid being rejected as foreign as they would be derived from the patients themselves. The study is published in the European Heart Journal. However, the researchers state that it could take a minimum of 5 to 10 years before clinical trials could start due to the many obstacles that must be overcome before using hiPSCs in humans is possible.

Although there has been advances in stem cell biology and tissue engineering, one of the major problems scientists have faced has been lack of good sources of human heart muscle cells and rejection by the immune system. Furthermore, until now, scientific have been unable to demonstrate that heart cells created from hiPSCs could integrate with existing cardiovascular tissue.

"What is new and exciting about our research is that we have shown that it's possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are health and young - the equivalent to the stage of his heart cells when he was just born," said Professor Lior Gepstein, Professor of Medicine (Cardiology) and Physiology at the Sohnis Research Laboratory for Cardiac Electrophysiology and Regenerative Medicine, Technion-Israel Institute of Technology and Rambam Medical Center in Haifa, Israel, who led the study.

In the study, Professor Gepstein, Ms Limor Zwi-Dantsis, and their colleagues retrieved skin cells from two male heart failure patients, aged 51 and 61 years, and reprogrammed the cells by delivering 3 transcription factors (Sox2, Oct4, and Klf4) in addition to a small molecule called valproic acid, to the cell nucleus. The team did not include a transcription factor called c-Myc as it is a known cancer-causing gene.

Professor Gepstein said:

In addition, the team used an alternative strategy involving a virus transferred reprogramming data to the cell nucleus. However, the team removed the virus after the information had been transferred in order to avoid insertional oncogenesis.

Read more here:
Skin Cells From Heart Failure Patients Made Into Healthy New Heart Muscle Cells

To Read More: Skin Cells From Heart Failure Patients Made Into Healthy New Heart Muscle Cells
categoriaSkin Stem Cells commentoComments Off on Skin Cells From Heart Failure Patients Made Into Healthy New Heart Muscle Cells | dataMay 26th, 2012
Read All

Human Skin Cells Turned Into Healthy Heart Muscle

By Sykes24Tracey

Scientists on Wednesday reported that they have for the first time taken skin cells from heart attacks patients and turned them into healthy heart tissue that could hopefully be used to one day repair damaged heart muscle.

The healthy, beating heart tissue was grown successfully in the lab from human-induced pluripotent stem cells (hiPSCs), and while scientists said they were not safe enough to put back into human patients, they appeared to work well with other cells when implanted into rats. HiPSCs are a recently discovered source far less controversial than use of embryonic stem cells. And, because the transplanted hiPSCs come from the individual, it could resolve the problems seen with tissue and organ rejection.

While the technique has shown promise in rats, the scientists say there are numerous obstacles to overcome and it could take up to ten years or longer before clinical trials could be available for humans. Even so, it is a significant advance in the quest for replacement cell therapy for heart failure patients.

More people are surviving following a heart attack than ever before and therefore the number of people living with a damaged heart and heart failure is increasing, Nicholas Mills, a consultant cardiologist at Edinburgh University, told The Guardian. Unfortunately, the body has only very limited capacity to repair the heart following a heart attack. There is therefore an urgent need to develop effective and safe treatments to regenerate the heart.

Recent research has shown that hiPSCs could be derived from young and healthy people and are capable of transforming into heart cells. However, researchers have not been able to obtain those cells from elderly and diseased patients. And until now, researchers have not been able to show that heart cells created from hiPSCs could integrate with existing heart tissue.

What is new and exciting about our research is that we have shown that its possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young the equivalent to the stage of his heart cells when he was just born, said lead researcher Professor Lior Gepstein, of Sohnis Research Laboratory for Cardiac Electrophysiology and Regenerative Medicine, Technion-Israel Institute of Technology and Rambam Medical Center in Haifa, Israel.

For their study, published in the European Heart Journal, Limor Zwi-Dantsis, a PhD student in the Sohnis Research Laboratory, Gepstein and colleagues took skin cells from two male heart failure patients (ages 51 and 61) and reprogrammed them with three genes (Sox2, Klf4 and Oct4), followed by a small molecule (valproic acid) to the cell nucleus.

The team also used an alternative strategy that involved a virus that delivered reprogramming information to the cell nucleus but which was capable of being removed afterward to avoid insertional oncogenesis.

Using these methods, the hiPSCs were able to differentiate to become cardiomyocytes (heart muscle cells) just as effectively as hiPSCs that had been developed from healthy, young volunteers. The researchers were then able to make cardiomyocytes develop into heart muscle tissue, which they cultured together with pre-existing cardiac tissue. The tissues were beating together within 48 hours, said the researchers.

The researchers transplanted the new tissue into the hearts of healthy rats and found that the grafted tissue started to establish connections with the cells in the host tissue.

Read more:
Human Skin Cells Turned Into Healthy Heart Muscle

To Read More: Human Skin Cells Turned Into Healthy Heart Muscle
categoriaSkin Stem Cells commentoComments Off on Human Skin Cells Turned Into Healthy Heart Muscle | dataMay 24th, 2012
Read All

Scientists Turn Skin Cells into Healthy Heart Cells

By raymumme

Dr. John D. Cunningham / Getty Images

In a medical first, scientists in Haifa, Israel, took skin cells from two heart failure patients and reprogrammed them into stem cells that generated healthy, beating heart muscle cells in the lab. Though human testing is likely a decade off, the hope is that such cells can be used to help people with heart failure repair their damaged hearts with their own skin cells.

In the current study, scientists first mixed the newly developed heart cells with pre-existing heart tissue within days, the cells were beating together. The heart tissue was then transplanted into rats, where it integrated with the rats healthy heart cells.

What is new and exciting about our research is that we have shown that its possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young the equivalent to the stage of his heart cells when he was just born, says lead researcherDr. Lior Gepstein, a senior clinical electrophysiologist at Rambam Medical Center in Israel, said in a statement.

The researchers were pleased to find that the cells made from the two heart failure patients, ages 51 and 61, generated heart muscle cells that were just as effective as those developed from healthy, young controls.

(MORE: Study During Beijing Olympics Shows How Pollution Harms the Heart)

If the technology works in human hearts, it could potentially prevent problems of immune rejection, since the cells would be the patients own. It would also avoid the moral issues surrounding the use of embryonic stem cells, since such reprogrammed stem cells or human induced pluripotent stem (iPS) cells do not use embryos.

But its still too early to predict whether the procedure could be successful humans. The new study involved cells from only two patients and were transplanted only into healthy animals. The authors note that human clinical trials are likely at least five or 10 years away. Further, creating iPS cells is not an easy or efficient process; its not clear whether enough cells could be made quickly enough to repair the broad-scale damage that occurs after a heart attack.

Reprogramming skin cells to become stem cells also introduces the potential for the cells to grow out of control and become cancerous. The Israeli researchers took additional steps removing certain transcription factors and viral factors to reduce the risk of cancer. But these hurdles would have to be revisited if the technique is tested in human patients.

This is an interesting paper, but very early and its really important for patients that the promise of such a technique is not oversold, John Martin, a professor of cardiovascular medicine at University College London, told Reuters.The chances of translation are slim and if it does work it would take around 15 years to come to clinic.

Continued here:
Scientists Turn Skin Cells into Healthy Heart Cells

To Read More: Scientists Turn Skin Cells into Healthy Heart Cells
categoriaSkin Stem Cells commentoComments Off on Scientists Turn Skin Cells into Healthy Heart Cells | dataMay 24th, 2012
Read All

Scientists convert skin cells into full functioning heart cells

By Sykes24Tracey

In the first procedure of its kind, skin cells taken from patients suffering from heart failure were reprogrammed and changed into heart muscle cells. Not only were the transformed cells healthy, but they were also transplanted into the hearts of rats and were able to integrate with the existing heart tissue.

Published in the European Heart Journal, the research examined the use of human-induced pluripotent stem cells (hiPSCs) to treat damaged hearts. HiPSCs are cells that are derived from other cells in a persons body.

We were able to show [in earlier studies] that you can take these hiPSCS from healthy heart patients and coax them into bonafide heart cells, lead author Lior Gepstein, professor of medicine (cardiology) and physiology at the Technion-Israel Institute of Technology and Rambam Medical Center in Haifa, Israel, told FoxNews.com. The question we asked in this study was whether you can do the same from an elderly individual that had suffered from advance heart failure.

Because hiPSCs are derived from the person in need of the stem cells, they could potentially help to bypass the painful process of rejection that many transplant patients go through. According to Gepstein, if this process is perfected, it could lead to much more localized treatments.

When there is significant damage from a heart attack, or with heart failure, where the heart doesnt pump enough blood into circulation, patients usually need a heart transplant, Gepstein said. But perhaps in the future, we can take a small sample of skin and convert them into stem cells specific to that patient. Then we can only replace the area with scar tissue rather than replace the dying heart.

In order to transform the skin cells into hiPSCs, Gepstein and his colleagues gave them a reprogramming cocktail, which involved delivering three genes (Sox2, Klf4 and Oct4), followed by a small molecule called valproic acid, to the nucleus of the cell.

This process turned the skin cells into heart muscle cells, or cardiomyocytes, which the researchers were able to subsequently turn into heart muscle tissue by culturing them together with cardiac tissue.

We converted the cells back into a state that resembles their early state in the embryo, Gepstein said. So they highly resemble the patients cells at the time they were born. When you give them proper conditions, they can become any type of cell in the body.

This area of study has advanced very rapidly, Gepstein added. You can take almost any type of adult cells - hair follicles, blood cells, etc. - and reprogram them to make hiPSCS cells. Skin cells are the easiest way to do it, and you dont need a lot of them.

Once the tissue had formed, it was transplanted into the hearts of healthy rats, where it successfully grafted and integrated with the existing tissue.

See the rest here:
Scientists convert skin cells into full functioning heart cells

To Read More: Scientists convert skin cells into full functioning heart cells
categoriaSkin Stem Cells commentoComments Off on Scientists convert skin cells into full functioning heart cells | dataMay 24th, 2012
Read All

Scientists Turn Skin Cells Into Cardiac Cells to Help Failing Hearts

By raymumme

WEDNESDAY, May 23 (HealthDay News) -- In a medical science first, researchers turned skin cells from heart failure patients into heart muscle cells that may then be used to fix damaged cardiac tissue.

The researchers said the achievement -- done initially with rats -- opens up the prospect of using heart failure patients' own stem cells -- a form of cell called human-induced pluripotent stem cells (hiPSCs) -- to repair damaged hearts. And since the reprogrammed stem cells would originate with the patient, their immune systems would not reject the cells as foreign, the researchers explained.

They added, however, that many obstacles must be overcome before it would be possible to use hiPSCs in humans this way, and any clinical trial would be at least five to 10 years away.

"We have shown that it's possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young -- the equivalent to the stage of his heart cells when he was just born," study leader Lior Gepstein said in a European Heart Journal news release. The study's findings are scheduled for online publication in the journal May 23.

Gepstein is professor of medicine (cardiology) and physiology at the Sohnis Research Laboratory for Cardiac Electrophysiology and Regenerative Medicine at the Technion Israel Institute of Technology and Rambam Medical Center in Haifa, Israel.

One expert in the United States applauded the achievement.

"The ability to source a patient's own skin cells and transform them into heart muscle is truly revolutionary," said Dr. Gregory Fontana, chairman of cardiothoracic surgery at Lenox Hill Hospital in New York City.

The results are "another step toward the treatment of heart failure with stem cells," he said. "Although further work is needed, this work represents another step closer to the clinic."

In the study, the researchers retrieved skin cells from two male heart failure patients, ages 51 and 61, and then reprogrammed them in the lab to develop into heart muscle tissue, which was then blended with pre-existing heart tissue. Within 24 to 48 hours, the tissues were beating together.

The new tissue was transplanted into healthy rat hearts and started to establish connections with the cells of the rat hearts. Success in animal experiments does not necessarily translate to success in humans, however.

Link:
Scientists Turn Skin Cells Into Cardiac Cells to Help Failing Hearts

To Read More: Scientists Turn Skin Cells Into Cardiac Cells to Help Failing Hearts
categoriaSkin Stem Cells commentoComments Off on Scientists Turn Skin Cells Into Cardiac Cells to Help Failing Hearts | dataMay 24th, 2012
Read All

Can Stem Cells Repair Heart Tissue?

By daniellenierenberg

People who suffer from heart failure could someday be able to use their own skin stem cells to regenerate their damaged heart tissue, according to a new Israeli study.

Researchers took stem cells from the skin of two patients with heart failure and genetically programmed them to become new heart muscle cells. They then transplanted the new cells into healthy rats and found that the cells integrated with cardiac tissue that already existed.

The study, published in European Heart Journal, marks the first time ever that scientists could use skin cells from people with heart failure and transform damaged heart tissue this way.

The newly generated cells turned out to be similar to embryonic stem cells, which can potentially be programmed to grow into any type of cell.

"What is new and exciting about our research is that we have shown that it's possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young the equivalent to the stage of his heart cells when he was just born," Dr. Lior Gepstein, lead researcher and a senior clinical electrophysiologist at Rambam Medical Center in Haifa, Israel, said in a news release.

The findings open up the possibility, the authors wrote, that people can use their own skin cells to repair their damaged hearts, which could prevent the problems associated with using embryonic stem cells.

"This approach has a number of attractive features," said Dr. Tom Povsic, an interventional cardiologist at Duke University Medical Center. "We can get the cells that you start with from the patient himself or herself. It avoids the ethical dilemma associated with embryonic stem cells and it removes the possibility of rejection of foreign stem cells by the immune system." Povsic was not involved with the Israeli study.

Another advantage of using skin cells is that other types of cells taken from patients themselves, such as bone marrow cells, could potentially lead to the development of unhealthy tissue.

"If a patient is already sick with heart disease, one of the reasons it may develop is that stem cells weren't able to repair the heart the way they should," Povsic added. Skin cells, he explained, are generally healthy.

"It is very exciting and very interesting, but we are far away from taking this to patients," said Dr. Marrick Kukin, director of the Heart Failure Program at St. Luke's-Roosevelt Hospital who was also not involved in the Israeli study.

Read the original:
Can Stem Cells Repair Heart Tissue?

To Read More: Can Stem Cells Repair Heart Tissue?
categoriaSkin Stem Cells commentoComments Off on Can Stem Cells Repair Heart Tissue? | dataMay 24th, 2012
Read All

Skin cells transformed into beating heart tissue, fueling heart failure treatment hopes

By NEVAGiles23

(CBS News) A new study of patients with heart failure found a novel treatment approach might reverse the damage that has long been considered irreversible: Fixing their damaged hearts using stem cells derived by their own skin cells.

Stem cells heal heart attack scars, regrow healthy muscle Stem cells cure heart failure? What "breakthrough" study shows

In what scientists are calling a first, skin cells were taken from heart failure patients and transformed into stem cells, which were then turned into heart muscle cells capable of beating - albeit in a petri dish.

The treatment approach has scientists buzzing because it avoids the risk of possible immune system rejection from transplanting "foreign" stem cells, since the cells came from patients' own bodies.

"What is new and exciting about our research is that we have shown that it's possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young - the equivalent to the stage of his heart cells when he was just born," the study's author Professor Lior Gepstein, professor of cardiology and physiology at the Technion-Israel Institute of Technology in Haifa, said in a news release.

Just how do skin cells become heart cells? Researchers took skin cells from two male patients with heart failure, a 51 and 61-year-old, and genetically reprogrammed them by injecting a cocktail of "transcription factors" and a virus into the nucleus of the skin cell, followed by removing the virus and transcription factors that have been linked to cancerous tumor growth. The goal was to reprogram the cells into human-induced pluripotent stem cells (hiPSCs) that could help repair hearts.

"One of the obstacles to using hiPSCs clinically in humans is the potential for the cells to develop out of control and become tumours," explained Prof Gepstein in using the technique.

Once in stem cell-form, the cells differentiated in a petri dish to become heart muscle cells called cardiomyocytes, which the researchers then combined with heart tissue and cultured them into healthy heart muscle tissue. Within 48 hours, the tissues were beating together.

"The tissue was behaving like a tiny microscopic cardiac tissue comprised of approximately 1000 cells in each beating area," Gepstein said in a statement.

The researchers then transplanted the new human tissue into rats, finding it grafted to the rat's host cardiac tissues. Their research is published in the May 22 issue of the European Heart Journal.

Link:
Skin cells transformed into beating heart tissue, fueling heart failure treatment hopes

To Read More: Skin cells transformed into beating heart tissue, fueling heart failure treatment hopes
categoriaSkin Stem Cells commentoComments Off on Skin cells transformed into beating heart tissue, fueling heart failure treatment hopes | dataMay 24th, 2012
Read All

International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …

By NEVAGiles23

CARLSBAD, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCOs pre-clinical therapeutic programs.

These results not only show the progress we have made in these important programs, but also demonstrate the broad application of human parthenogenetic stem cells in the development of treatments for incurable diseases

Firstly, the application of A9 dopaminergic neurons derived from human parthenogenetic stem cells (hpSC) for the treatment of Parkinsons disease. Demonstrating functional dopaminergic neurons in vivo represents an important milestone towards the goal of creating well characterized populations of cells that could be used to develop a treatment for Parkinsons.

Secondly, the differentiation of hpSC and embryonic stem cells into cornea-like constructs for use in transplantation therapy and the in vitro study of ocular drug absorption. There are approximately ten million people worldwide who are blind as a result of damage to their cornea. Generating human corneas from a pluripotent stem cell source should increase the likelihood that people will receive treatment in the future even in the absence of suitable tissue from eye banks.

Lastly, the in vivo and in vitro characterization of immature hepatocyte derived from hpSC. Such cells could be used to develop a treatment for individuals with a liver that has been damaged by disease or sufferers of genetic disorders that inhibit normal liver function. In both cases, implanting healthy hepatocyte cells could treat the underlying disease and prolong the life of the individual.

These results not only show the progress we have made in these important programs, but also demonstrate the broad application of human parthenogenetic stem cells in the development of treatments for incurable diseases, says Dr. Ruslan Semechkin, Vice President of Research and Development.

The presentations will take place at the 15th Annual Meeting of American Society of Gene and Cell Therapy, in Philadelphia at 3:30 p.m. on Thursday, May 17th.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Read this article:
International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene ...

To Read More: International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene …
categoriaSkin Stem Cells commentoComments Off on International Stem Cell Corporation Scientists to Present Pre-Clinical Research Results at American Society of Gene … | dataMay 16th, 2012
Read All

International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic …

By LizaAVILA

CARLSBAD, Calif.--(BUSINESS WIRE)--

International Stem Cell Corporation (OTCBB: ISCO.OB - News) http://www.internationalstemcell.com today announced that the Company has developed new technologies to commercialize the use of human parthenogenetic stem cells (hpSC) to treat human diseases. The methods announced today are capable of producing populations of stem cells and their therapeutically valuable derivatives not only to a higher level of purity but also at a cost that is approximately several times lower than previously reported techniques.

ISCOs research team has developed a new method to derive high-purity populations of neural stem cells (NSC) from hpSC and further differentiate them into dopaminergic neurons. This method is capable of generating sufficient quantities of neuronal cells for ISCOs pre-clinical and clinical studies and is highly efficient as it requires substantially less time and labor in addition to using fewer costly materials than traditional methods. ISCOs technologies make possible the creation of billions of neuronal cells necessary for conducting such studies from a small batch of stem cells.

ISCO has also announced today that it has developed a new high-throughput cell culture method for growing human parthenogenetic stem cells (hpSC) in large quantities. This new technique is easily scalable and can produce the quantities of cGMP grade hpSC necessary for commercial and therapeutic applications.

One of the most challenging issues in commercializing stem cell based treatments is creating high-purity populations of stem cell derivatives at a reasonable cost. I believe the new methods we have developed solve this important problem and help position us for future clinical studies, says Dr. Ruslan Semechkin, Vice President, R&D.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, the potential benefits of research programs and new manufacturing technologies, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and technologies regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Visit link:
International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic ...

To Read More: International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic …
categoriaSkin Stem Cells commentoComments Off on International Stem Cell Corporation Announces New Stem Cell Manufacturing Technologies to Support its Therapeutic … | dataMay 10th, 2012
Read All

Stem cell collaboration could set stage for company’s growth

By Sykes24Tracey

A stem cell breakthrough at UCLA could mark a big step for a biopharmaceutical company to use its proprietary technology to forge partnerships with pharmaceutical companies and other research institutions.

Fibrocell Sciences technology isolates, purifies and multiplies a patients fibroblast cells, connective skin cells that make collagen. In a research collaboration with the company, UCLA used the technology to isolate, identify and increase the number of different skin cell types, which lead to two rare adult stem cell-like subpopulations being identified in adult human skin SSEA3-expressing regeneration-associated cells associated with skin regeneration after injuries and mesenchymal adult stem cells.

The findings could have broad applications for personalized medicine. Currently, adult stem cells are derived from adipose tissue and bone marrow. Using mesenchymal stem cells would be less invasive and could be more efficient. Mesenchymal stem cells are being used in research to develop osteoblasts, or bone cells; chondrocytes, or cartilage cells; and adipocytes, or fat cells.

David Pernock, the chairman and CEO of Fibrocell, said the move could mark a significant step in the companys growth.

Follow this link:
Stem cell collaboration could set stage for company’s growth

To Read More: Stem cell collaboration could set stage for company’s growth
categoriaSkin Stem Cells commentoComments Off on Stem cell collaboration could set stage for company’s growth | dataMay 10th, 2012
Read All

Boston scientists grow lung tissue from cystic fibrosis patients’ skin cells

By JoanneRUSSELL25

By Carolyn Y. Johnson, Globe Staff

Two teams of Boston scientists have developed new ways to turn stem cells into different types of lung tissue, surmounting a major hurdle for scientists trying to harness the power of stem cell biology to study and develop treatments for major lung diseases.

One team then used skin cells from cystic fibrosis patients to create embryonic-like stem cells, then working in lab dishes used those cells to grow tissue that lines the airways and contains a defect responsible for the rare, fatal disease. The technique -- essentially a recipe for growing such lung tissue -- could provide a powerful platform to screen drugs and study the biology of the disease.

Growing lung tissue in the laboratory has long been a goal of stem cell scientists, but has been more technically difficult than growing other types of tissues, such as brain cells or heart cells. Such lung tissue is valuable because it could be used to screen potential drugs and more closely probe the problems that underlie diseases such as asthma, emphysema, and rare genetic diseases. Such techniques may also one day help researchers grow replacement tissues and devise ways to restore or repair injured lung tissue.

A team led by Massachusetts General Hospital researchers created lung tissue from a patient with the genetic mutation that most commonly underlies cystic fibrosis and researchers hope the technique will also be a powerful tool to study other diseases that affect the airway tissue, such as asthma and lung cancer. The other team, led by Boston University School of Medicine scientists, was able to derive cells that form the delicate air sacs of the lung from mouse embryonic stem cells. The team is hoping to refine the recipe for making the cells so that they can be used to derive lung tissue from a bank of 100 stem cell lines of patients with lung disease. Both papers were published Thursday in the journal Cell Stem Cell.

Vertex Pharmaceuticals, a Cambridge biotechnology company, earlier this year received approval for Kalydeco -- the first drug to directly target the underlying cause of cystic fibrosis. That compound was discovered by screening massive numbers of potential drugs against cells engineered to carry the same defect that underlies cystic fibrosis.

We had to use engineered cells, and certainly using more native human cells ... would be potentially beneficial, said Dr. Frederick Van Goor, head of biology for Vertexs cystic fibrosis research program. We had to rely on donor tissue obtained from patients with cystic fibrosis, and its a bit more challenging, because the number of donor lungs you can get and the number of cells you can derive from there are more limited.

Van Goor said it was too soon to say whether the company would use the new technology in screening, but noted that the tests the company had used to determine whether a drug was likely to work against the disease had, in some cases, given scientists false leads. Some molecules that worked on the engineered cells did not work in the complicated biology of the lung.

Its a significant event for the lung field, said Dr. Thiennu Vu, associate professor of medicine at the University of California San Francisco, who was not involved in the research. She added that much work remains before such cells could be used to repair or replace damaged tissue, and even before such cells would necessarily be useful for drug screening. It will be important, she said, to refine the recipe to ensure that the technique yields pure populations of the specific types of functional lung cells.

In the competitive world of science, where credit for being the first to do something is crucially important, the two research teams accomplishments are an unusual example of competitors turning into collaborators -- forging a relationship that both teams felt helped speed up progress.

See original here:
Boston scientists grow lung tissue from cystic fibrosis patients’ skin cells

To Read More: Boston scientists grow lung tissue from cystic fibrosis patients’ skin cells
categoriaSkin Stem Cells commentoComments Off on Boston scientists grow lung tissue from cystic fibrosis patients’ skin cells | dataMay 10th, 2012
Read All

NY medical schools chart progress with stem cells

By LizaAVILA

ALBANY, N.Y. Almost halfway through a $600 million state program supporting stem cell research, eight medical schools around New York are reporting progress on projects such as replicating liver cells and eradicating leukemia cells.

Only on msnbc.com

A new report from Associated Medical Schools of New York updates work at the institutions where hundreds of researchers are starting to unravel causes and potential treatments for conditions ranging from autism to heart disease and cancer. Stem cells are self-renewing and have the ability to develop into other types of cells.

The Mount Sinai School of Medicine reported finding a method to transform human skin cells into stem cells and turned differentiated human stem cells into heart cells. Those findings are expected to result in better understanding of how heart disease develops and allow initial testing of new treatments on stem cells before they are used on human subjects.

Dr. Ihor Lemischka, director of the Black Family Stem Cell Institute at Mount Sinai, said recreating heart cells in a dish from a patient with LEOPARD Syndrome, a disease caused by a genetic mutation, has opened ongoing avenues for researching the disease and screening potential drugs.

"It was a major achievement," Lemischka said. The initial work was reported in June 2010 in the journal Nature.

The shared research facility at Mount Sinai supports the work at 80 different labs, Lemischka said.

The Empire State Stem Cell Program was intended to fund projects in early stages, including those that initially have been unable to get federal or private funding. Grants have also been used for capital projects like renovating labs and establishing new stem cell centers.

The Albert Einstein College of Medicine reported replicating liver cells that could help reduce the need for liver transplants using live donors and cadavers.

Dr. Allen Spiegel said 12 new researchers have been hired with state funding at the Bronx school, which also lists anemia, brain disorders, heart disease and obesity among its stem cell research subjects.

Go here to see the original:
NY medical schools chart progress with stem cells

To Read More: NY medical schools chart progress with stem cells
categoriaSkin Stem Cells commentoComments Off on NY medical schools chart progress with stem cells | dataMay 10th, 2012
Read All

Iranian researcher helps treating muscular dystrophy using stem cells

By daniellenierenberg

Source: ISNA, Tehran

Iranian researcher and lecturer Radbod Darabi jointly with his collogues from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process which for the first time makes the production of human muscle cells from stem cells efficient and effective.

Radbod Darabi, MD, PhD with Rita Perlingeiro, PhD. (Credit: Image courtesy of University of Minnesota Academic Health Center)

The research outlines the strategy for the development of a rapidly dividing population of muscle-forming cells derived from induced pluripotent (iPS) cells.

IPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.

This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.

According to the researchers, there has been a significant lag in translating studies using mouse stem cells into therapeutically relevant studies involving human stem cells.

This lag has dramatically limited the development of cell therapies or clinical trials for human patients.

The latest research from the University of Minnesota provides the proof-of-principle for treating muscular dystrophy with human iPS cells, setting the stage for future human clinical trials.

As the researchers noted one of the biggest barriers to the development of cell-based therapies for neuromuscular disorders like muscular dystrophy has been obtaining sufficient muscle progenitor cells to produce a therapeutically effective response.

Read the rest here:
Iranian researcher helps treating muscular dystrophy using stem cells

To Read More: Iranian researcher helps treating muscular dystrophy using stem cells
categoriaSkin Stem Cells commentoComments Off on Iranian researcher helps treating muscular dystrophy using stem cells | dataMay 7th, 2012
Read All

4-Hour, Whole-Body 'Face-Lift' Uses Patient's Own Fat, Stem Cells

By JoanneRUSSELL25

May 4, 2012 9:27am

ABC News Paula Faris reports:

It is a medical claim that sounds like science fiction. Walk into a plastic surgeons office for a face-lift and walk out roughly four hours later with a whole-body makeover that required no incision and leaves you with no scars.

But some doctors say that fiction is now reality in the form of a stem-cell makeover, a procedure that uses the fat and stem cells from one part of the body to revamp another part of the body, all in a single office visit.

Such a claim convinced Debra Kerr to try the procedure herself in hopes of achieving a younger look. My eyes are looking heavier, and the lines are so pronounced and gravitys really taken over, Kerr, 55, said. I want to look as good and as young as I really feel.

Kerr, a skin-care specialist from Ohio, underwent a stem-cell makeover in which fat was removed from her waist via liposuction. The fat was then spun in the lab to concentrate its stem cells and, hours later, injected into Kerrs face and breasts.

Were taking a patients own fatty tissue, and we are just repositioning it in another part of their body, said Dr. Sharon McQuillan, a physician and founder of the Ageless Institute in Aventura, Fla., where Kerr had her procedure done.

Courtesy Dr. Sharon McQuillan

Because the makeover uses a patients own stem cells, there is virtually no risk that the body will reject the transfer, according to doctors like McQuillan who perform the procedure.

This enhancement will be enough to make her [Kerr] happy, McQuillan said. She wont have any scars. She doesnt really have any of the risks associated with general anesthesia or a full face lift.

More here:
4-Hour, Whole-Body 'Face-Lift' Uses Patient's Own Fat, Stem Cells

To Read More: 4-Hour, Whole-Body 'Face-Lift' Uses Patient's Own Fat, Stem Cells
categoriaSkin Stem Cells commentoComments Off on 4-Hour, Whole-Body 'Face-Lift' Uses Patient's Own Fat, Stem Cells | dataMay 6th, 2012
Read All

U of M researchers develop new muscular dystrophy treatment approach using human stem cells

By JoanneRUSSELL25

Public release date: 3-May-2012 [ | E-mail | Share ]

Contact: Caroline Marin crmarin@umn.edu 612-624-5680 University of Minnesota Academic Health Center

MINNEAPOLIS/SAINT PAUL (May 4, 2012) Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that for the first time makes the production of human muscle cells from stem cells efficient and effective.

The research, published today in Cell Stem Cell, outlines the strategy for the development of a rapidly dividing population of skeletal myogenic progenitor cells (muscle-forming cells) derived from induced pluripotent (iPS) cells. iPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.

This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.

According to U of M researchers who were also the first to use ES cells from mice to treat muscular dystrophy there has been a significant lag in translating studies using mouse stem cells into therapeutically relevant studies involving human stem cells. This lag has dramatically limited the development of cell therapies or clinical trials for human patients.

The latest research from the U of M provides the proof-of-principle for treating muscular dystrophy with human iPS cells, setting the stage for future human clinical trials.

"One of the biggest barriers to the development of cell-based therapies for neuromuscular disorders like muscular dystrophy has been obtaining sufficient muscle progenitor cells to produce a therapeutically effective response," said principal investigator Rita Perlingeiro, Ph.D., associate professor of medicine in the Medical School's Division of Cardiology. "Up until now, deriving engraftable skeletal muscle stem cells from human pluripotent stem cells hasn't been possible. Our results demonstrate that it is indeed possible and sets the stage for the development of a clinically meaningful treatment approach."

Upon transplantation into mice suffering from muscular dystrophy, human skeletal myogenic progenitor cells provided both extensive and long-term muscle regeneration which resulted in improved muscle function.

To achieve their results, U of M researchers genetically modified two well-characterized human iPS cell lines and an existing human ES cell line with the PAX7 gene. This allowed them to regulate levels of the Pax7 protein, which is essential for the regeneration of skeletal muscle tissue after damage. The researchers found this regulation could prompt nave ES and iPS cells to differentiate into muscle-forming cells.

Continue reading here:
U of M researchers develop new muscular dystrophy treatment approach using human stem cells

To Read More: U of M researchers develop new muscular dystrophy treatment approach using human stem cells
categoriaSkin Stem Cells commentoComments Off on U of M researchers develop new muscular dystrophy treatment approach using human stem cells | dataMay 6th, 2012
Read All

New muscular dystrophy treatment approach developed using human stem cells

By Dr. Matthew Watson

ScienceDaily (May 4, 2012) Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that -- for the first time -- makes the production of human muscle cells from stem cells efficient and effective.

The research, published May 4 in Cell Stem Cell, outlines the strategy for the development of a rapidly dividing population of skeletal myogenic progenitor cells (muscle-forming cells) derived from induced pluripotent (iPS) cells. iPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.

This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.

According to U of M researchers -- who were also the first to use ES cells from mice to treat muscular dystrophy -- there has been a significant lag in translating studies using mouse stem cells into therapeutically relevant studies involving human stem cells. This lag has dramatically limited the development of cell therapies or clinical trials for human patients.

The latest research from the U of M provides the proof-of-principle for treating muscular dystrophy with human iPS cells, setting the stage for future human clinical trials.

"One of the biggest barriers to the development of cell-based therapies for neuromuscular disorders like muscular dystrophy has been obtaining sufficient muscle progenitor cells to produce a therapeutically effective response," said principal investigator Rita Perlingeiro, Ph.D., associate professor of medicine in the Medical School's Division of Cardiology. "Up until now, deriving engraftable skeletal muscle stem cells from human pluripotent stem cells hasn't been possible. Our results demonstrate that it is indeed possible and sets the stage for the development of a clinically meaningful treatment approach."

Upon transplantation into mice suffering from muscular dystrophy, human skeletal myogenic progenitor cells provided both extensive and long-term muscle regeneration which resulted in improved muscle function.

To achieve their results, U of M researchers genetically modified two well-characterized human iPS cell lines and an existing human ES cell line with the PAX7 gene. This allowed them to regulate levels of the Pax7 protein, which is essential for the regeneration of skeletal muscle tissue after damage. The researchers found this regulation could prompt nave ES and iPS cells to differentiate into muscle-forming cells.

Up until this point, researchers had struggled to make muscle efficiently from ES and iPS cells. PAX7 -- induced at exactly the right time -- helped determine the fate of human ES and iPS cells, pushing them into becoming human muscle progenitor cells.

Once Dr. Perlingeiro's team was able to pinpoint the optimal timing of differentiation, the cells were well suited to the regrowth needed to treat conditions such as muscular dystrophy. In fact, Pax7-induced muscle progenitors were far more effective than human myoblasts at improving muscle function. Myoblasts, which are cell cultures derived from adult muscle biopsies, had previously been tested in clinical trials for muscular dystrophy, however the myoblasts did not persist after transplantation.

Read more from the original source:
New muscular dystrophy treatment approach developed using human stem cells

To Read More: New muscular dystrophy treatment approach developed using human stem cells
categoriaSkin Stem Cells commentoComments Off on New muscular dystrophy treatment approach developed using human stem cells | dataMay 6th, 2012
Read All

Researchers develop new muscular dystrophy treatment approach using human stem cells

By raymumme

Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that for the first time makes the production of human muscle cells from stem cells efficient and effective.

The research, published today in Cell Stem Cell, outlines the strategy for the development of a rapidly dividing population of skeletal myogenic progenitor cells (muscle-forming cells) derived from induced pluripotent (iPS) cells. iPS cells have all of the potential of embryonic stem (ES) cells, but are derived by reprogramming skin cells. They can be patient-specific, which renders them unlikely to be rejected, and do not involve the destruction of embryos.

This is the first time that human stem cells have been shown to be effective in the treatment of muscular dystrophy.

According to U of M researchers who were also the first to use ES cells from mice to treat muscular dystrophy there has been a significant lag in translating studies using mouse stem cells into therapeutically relevant studies involving human stem cells. This lag has dramatically limited the development of cell therapies or clinical trials for human patients.

The latest research from the U of M provides the proof-of-principle for treating muscular dystrophy with human iPS cells, setting the stage for future human clinical trials.

"One of the biggest barriers to the development of cell-based therapies for neuromuscular disorders like muscular dystrophy has been obtaining sufficient muscle progenitor cells to produce a therapeutically effective response," said principal investigator Rita Perlingeiro, Ph.D., associate professor of medicine in the Medical School's Division of Cardiology. "Up until now, deriving engraftable skeletal muscle stem cells from human pluripotent stem cells hasn't been possible. Our results demonstrate that it is indeed possible and sets the stage for the development of a clinically meaningful treatment approach."

Upon transplantation into mice suffering from muscular dystrophy, human skeletal myogenic progenitor cells provided both extensive and long-term muscle regeneration which resulted in improved muscle function.

To achieve their results, U of M researchers genetically modified two well-characterized human iPS cell lines and an existing human ES cell line with the PAX7 gene. This allowed them to regulate levels of the Pax7 protein, which is essential for the regeneration of skeletal muscle tissue after damage. The researchers found this regulation could prompt nave ES and iPS cells to differentiate into muscle-forming cells.

Up until this point, researchers had struggled to make muscle efficiently from ES and iPS cells. PAX7 induced at exactly the right time helped determine the fate of human ES and iPS cells, pushing them into becoming human muscle progenitor cells.

Once Dr. Perlingeiro's team was able to pinpoint the optimal timing of differentiation, the cells were well suited to the regrowth needed to treat conditions such as muscular dystrophy. In fact, Pax7-induced muscle progenitors were far more effective than human myoblasts at improving muscle function. Myoblasts, which are cell cultures derived from adult muscle biopsies, had previously been tested in clinical trials for muscular dystrophy, however the myoblasts did not persist after transplantation.

Read the original post:
Researchers develop new muscular dystrophy treatment approach using human stem cells

To Read More: Researchers develop new muscular dystrophy treatment approach using human stem cells
categoriaSkin Stem Cells commentoComments Off on Researchers develop new muscular dystrophy treatment approach using human stem cells | dataMay 6th, 2012
Read All

Bellevue doctor tests stem-cell cream as anti-aging therapy

By daniellenierenberg

by JEAN ENERSEN / KING 5 News

KING5.com

Posted on April 27, 2012 at 11:01 PM

A Bellevue doctor is one of only two researchers in the country testing stem cells as an anti-aging treatment.

Working with volunteer patients, Dr. Fredric Stern extracts stem cells with a liposuction-like procedure. The cells are then mixed with a special medium.

"Half is saved cyrogenically for future use and the other half is shipped to the laboratory in Arizona where on that end the stem cells are grown further," Stern said.

The end product goes into a cream called tropoelastin. The hope is that high concentrations of a patient's own stem cells in the cream will boost the skink's ability to repair itself.

If the eye cream proves successful in the eight-week study, the company will also offer a facial cream. Both could be available within a few months.

Stern said he expects the price to be comparable to high-end cosmetic products that typically cost hundreds of dollars.

Stern said the skin treatment is just the beginning. He said wound care is another possible use.

Read more:
Bellevue doctor tests stem-cell cream as anti-aging therapy

To Read More: Bellevue doctor tests stem-cell cream as anti-aging therapy
categoriaSkin Stem Cells commentoComments Off on Bellevue doctor tests stem-cell cream as anti-aging therapy | dataApril 29th, 2012
Read All

Page 101«..1020..100101102103..»


Copyright :: 2024